A Phase 1/1b Study of IAM1363 in HER2 Cancers
for HER2 Mutation-Related Tumors
29 locations incl. La Jolla
Sponsor: Iambic Therapeutics, Inc
Sex: All·Age: 18+
Code: NCT06253871·Phase 1·Recruiting·Listed Feb 2024
MD Anderson Cancer Center at Texas Medical Center
Clinical research site in Houston, Texas · 1515 HOLCOMBE BLVD UNIT 428, HOUSTON, TX 77030-4028 · (713) 794-1464 · Website
As of July 2026, 373 paid clinical trials are recruiting at MD Anderson Cancer Center at Texas Medical Center in Houston, Texas. Active studies at this site cover conditions such as Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at MD Anderson Cancer Center at Texas Medical Center (373)
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
for Leukemia, Myeloid, Acute
30 locations incl. Newport Beach
Sponsor: Sumitomo Pharma America, Inc.
Sex: All·Age: 12+
Code: NCT04988555·Phase 1, Phase 2·Recruiting·Listed Aug 2021
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
for Mesothelioma
22 locations incl. Phoenix
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT05245500·Phase 1·Recruiting·Listed Feb 2022
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
for Advanced Urothelial Cancer
10 locations incl. Duarte
Sponsor: Generate Biomedicines
Sex: All·Age: 18+
Code: NCT07484022·Phase 1·Recruiting·Listed Mar 2026
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
for Meningioma
12 locations incl. Birmingham
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT07428616·Phase 2·Recruiting·Listed Feb 2026
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
for GIST - Gastrointestinal Stromal Tumor
16 locations incl. Los Angeles
Sponsor: Kumquat Biosciences Inc.
Sex: All·Age: 18+
Code: NCT07406633·Phase 2·Recruiting·Listed Feb 2026
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
for HER2 Expressing Solid Tumors
10 locations incl. Los Angeles
Sponsor: Vironexis Biotherapeutics Inc.
Sex: All·Age: 18+
Code: NCT07192432·Phase 1, Phase 2·Recruiting·Listed Sep 2025
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
for Invasive Mold Infections
19 locations incl. Birmingham
Sponsor: Basilea Pharmaceutica
Sex: All·Age: 18+
Code: NCT06925321·Phase 3·Recruiting·Listed Apr 2025
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
for Ewing Sarcoma
18 locations incl. Beverly Hills
Sponsor: Inhibrx Biosciences, Inc
Sex: All·Age: 12 - 85
Code: NCT03715933·Phase 1·Recruiting·Listed Oct 2018
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
for Pemphigus Vulgaris
10 locations incl. Redwood City
Sponsor: Cabaletta Bio
Sex: All·Age: 18+
Code: NCT04422912·Phase 1, Phase 2·Recruiting·Listed Jun 2020
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
for Advanced Solid Tumor
14 locations incl. San Francisco
Sponsor: Debiopharm International SA
Sex: All·Age: 12+
Code: NCT04855656·Phase 1·Recruiting·Listed Apr 2021
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
for Endometrial Cancer
12 locations incl. Phoenix
Sponsor: Iovance Biotherapeutics, Inc.
Sex: Female·Age: 18 - 70
Code: NCT06481592·Phase 2·Recruiting·Listed Jul 2024
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
for Advanced Solid Tumor
13 locations incl. Los Angeles
Sponsor: Volastra Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT05902988·Phase 1, Phase 2·Recruiting·Listed Jun 2023
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
for Advanced Solid Tumor
6 locations incl. Boston
Sponsor: Ipsen
Sex: All·Age: 18+
Code: NCT07213830·Phase 1, Phase 2·Recruiting·Listed Oct 2025
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
for Non-Small Cell Lung Cancer
5 locations incl. La Jolla
Sponsor: Fate Therapeutics
Sex: All·Age: 18+
Code: NCT07216105·Phase 1·Recruiting·Listed Oct 2025
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
for Advanced HR+/HER2- Breast Cancer
8 locations incl. Los Angeles
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 100
Code: NCT06726148·Phase 1, Phase 2·Recruiting·Listed Dec 2024
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
for Tumor Skin
8 locations incl. Los Angeles
Sponsor: Obsidian Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06060613·Phase 1, Phase 2·Recruiting·Listed Sep 2023
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
for Non-Hodgkin Lymphoma
6 locations incl. San Francisco
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT05169515·Phase 1·Recruiting·Listed Dec 2021
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
for Colorectal Cancer
4 locations incl. Providence
Sponsor: EMD Serono Research & Development Institute, Inc.
Sex: All·Age: 18+
Code: NCT05464030·Phase 1·Recruiting·Listed Jul 2022
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
for Advanced Solid Tumors
8 locations incl. Jacksonville
Sponsor: Vividion Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT05954312·Phase 1·Recruiting·Listed Jul 2023
Study of APR-1051 in Patients With Advanced Solid Tumors
for Advanced Solid Tumor
3 locations incl. Houston
Sponsor: Aprea Therapeutics
Sex: All·Age: 18+
Code: NCT06260514·Phase 1·Recruiting·Listed Feb 2024
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
for VEXAS
9 locations incl. Scottsdale
Sponsor: Swedish Orphan Biovitrum
Sex: All·Age: 18+
Code: NCT06782373·Phase 2·Recruiting·Listed Jan 2025
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
for Low-grade Upper Tract Urothelial Carcinoma
9 locations incl. Scottsdale
Sponsor: Ferring Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06668493·Phase 1, Phase 2·Recruiting·Listed Oct 2024
Comprehensive Assessment of Cancer Theranostic Response
for Prostate Cancer
2 locations incl. New York
Sponsor: AIQ Solutions
Sex: Male·Age: 18+
Code: NCT06815354·Recruiting·Listed Feb 2025
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
for Glioblastoma, IDH-wildtype
7 locations incl. Detroit
Sponsor: Orbus Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT05879367·Phase 1·Recruiting·Listed May 2023
A Study of IBI363 in Subjects with Advanced Solid Malignancies
for Melanoma
9 locations incl. San Francisco
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sex: All·Age: 18+
Code: NCT06281678·Phase 2·Recruiting·Listed Feb 2024
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
for Relapsed Adult AML
1 location in Houston
Sponsor: Pacylex Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06613217·Phase 1·Recruiting·Listed Sep 2024
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
for Hematologic Malignancies
2 locations incl. Jacksonville
Sponsor: Ascentage Pharma Group Inc.
Sex: All·Age: 18+
Code: NCT03537482·EARLY_Phase 1·Recruiting·Listed May 2018
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
for Clear Cell Renal Cell Carcinoma
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18 - 70
Code: NCT07564232·Phase 1·Recruiting·Listed May 2026
Baseline Anxiety Trajectories in Pediatric Radiation Therapy Observational Cohort
for Anxiety
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 2 - 12
Code: NCT07575815·Recruiting·Listed May 2026
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
for T-cell Acute Lymphoblastic Leukemia
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 12 - 30
Code: NCT07513129·Phase 1·Recruiting·Listed Apr 2026
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
for AML
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18+
Code: NCT07508982·Phase 1, Phase 2·Recruiting·Listed Apr 2026
Radiofrequency Ablation For Recurrent Parathyroid Carcinoma
for Recurrent Parathyroid Carcinoma
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18+
Code: NCT07475780·Recruiting·Listed Mar 2026
Trial of Spiritual Care Interventions for Patients With Cancer
for Advanced Cancer
3 locations incl. New York
Sponsor: Weill Medical College of Cornell University
Sex: All·Age: 18+
Code: NCT07408310·Recruiting·Listed Feb 2026
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
for Anatomic Stage I Breast Cancer AJCC v8
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18+
Code: NCT07407920·Phase 2·Recruiting·Listed Feb 2026
A Study of Revumenib and Mezigdomide in People With Leukemia
for Leukemia
10 locations incl. Duarte
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All·Age: 12+
Code: NCT07356154·Phase 1, Phase 2·Recruiting·Listed Jan 2026
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
for Cervical Carcinoma
18 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 25+·Accepts healthy volunteers
Code: NCT07281430·Recruiting·Listed Dec 2025
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
for Breast Cancer
1105 locations incl. Anchorage
Sponsor: NRG Oncology
Sex: Female·Age: 18 - 60
Code: NCT05879926·Phase 3·Recruiting·Listed May 2023
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
for Stage III Colon Cancer
922 locations incl. Fairhope
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
for Anatomic Stage II Breast Cancer AJCC v8
776 locations incl. Fairhope
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023
Showing the 40 most relevant of 373 recruiting trials at this site. Browse all with filters →
More research sites in Houston
- MD Anderson Cancer Center (422 trials)
- M D Anderson Cancer Center (272 trials)
- Baylor College of Medicine (197 trials)
- The University of Texas Health Science Center at Houston (185 trials)
- The University of Texas MD Anderson Cancer Center (131 trials)
- Houston Methodist Hospital (128 trials)
- Texas Children's Hospital (113 trials)
- The University of Texas M. D. Anderson Cancer Center (85 trials)
- University of Texas MD Anderson Cancer Center (83 trials)
- UT MD Anderson Cancer Center (62 trials)